|
|
 |
|
Viewing report
|
|
|
|
U.S. Lipid Therapeutics Market
Frost & Sullivan, Nov 2005
Quest for Treatment Goal Achievement Creates New Trends in Therapy
Although drugs that can positively regulate cholesterol levels and reduce the risk for cardiovascular disease have been in the market for over three decades, a sizable portion of the dyslipidemic population remains untreated. The growing prevalence of dyslipidemia in the United States requires the development of new drug therapies as an adjunct to dietary and lifestyle modifications to address the entirety of the lipid profile. Furthermore, the continued changing of therapeutic guidelines by the medical community as well as the need to increase the number of patients meeting their set treatment goals are likely to create new trends in the treatment of dyslipidemia.
This Frost & Sullivan research service analyzes the U.S. lipid therapeutics market. It provides detailed insights into recent developments and trends. The study also discusses the prevailing market drivers as well as industry challenges and offers an overview of the market revenues and shares.
Generic Statins Create Branded Blockbuster Void
'Large levels of market success are expected to be reserved for products that are successfully able to differentiate themselves from the rest of the field,' says the analyst of this research service. 'Products that are effective, with few side effects, and have a competitive price should aid in sustaining the revenue growth of the cholesterol drug industry.'
With two major, multi-billion dollar statin products going generic in 2006, the industry will have to find new ways and new areas to devise their blockbuster drug products. There are four products currently marketed in the United States that are forecast to reach the blockbuster $1 billion mark by 2011. Newer product types, as well as the advocating of aggressive lipid management by the medical community are expected to aid in product growth outside of statin monotherapy.
Increased Use of Cross-Class Combinations is Likely to Induce Growth in the Lipid Therapeutics Market
The monotherapeutic use of statin drugs is the typical first line drug treatment for cholesterol disorders and has created an enormous amount of revenue growth for the market. With several major statin products losing patent protection during the forecast period, their contribution to market growth is expected to slow.
'The co-administration of drugs is benefiting other areas through increased use of the non-statin classes, especially cholesterol absorption inhibitors, fibrates, and nicotinic acid derivatives,' states the analyst. 'Newer technologies, such as single pill combinations, are also expected to have an increased contribution to market growth in the future.'
|
|
|
|
